Eisai Articles
Japan's Eisai to set up parenteral facility in China
28 April 2013
MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world
8 April 2013
Growing patient population to drive Mexican breast cancer market
20 February 2013
Treatment landscape for thyroid carcinoma will change dramatically through 2021; report
5 February 2013
US and European oncologists see novel chemotherapies as best hope for soft tissue sarcoma
30 January 2013
Eisai disagrees with Germany's IQWiG report on epilepsy drug Fycompa
19 December 2012
Takeda sells non-Colcrys URL Pharma generic business to Sun Pharma; Eisai divests Gliadel Wafer in USA
17 December 2012
Eisai in neurological disease discovery alliance with UCL
13 December 2012
Scottish Medicines Consortium approves Eisai's Fycompa and Novartis' Lucentis for DME
11 December 2012
San Antonio breast cancer meeting highlights
10 December 2012
Insights on the US Alzheimer's disease market
3 December 2012
Santen in ophthalmics deal with Eisai; Sets up new company in China
26 September 2012
Public Citizen sues FDA for failing to ban dangerous dose of Aricept
7 September 2012
Eisai gets South Korean approval for breast cancer drug Halaven
4 September 2012
Positive final pivotal Ph III results for Eisai's Fycompa
21 August 2012
Germany's G-BA backs Eisai's Halaven; IQWiG finds some added benefit for Eliquis and rilpivirine
23 April 2012
Eisai enters deals with Valeant and Minophagen
4 April 2012
Arena Pharma updates on lorcaserin filings in EU and USA
27 March 2012
Added benefit of Eisai’s Halaven not proven, says Germany’s IQWiG
17 February 2012
Actavis to debut generic Aricept in EU markets as patents expire
16 February 2012
FDA wants more info on Menveo; advisory negative on Dacogen
13 February 2012
Eisai gets Lunesta approval in Japan, launches Fostoin
20 January 2012
FDA updates on obesity drug candidates
11 January 2012
Arena files complete response on lorcaserin
5 January 2012
Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad
28 December 2011
US gastroenterologists see significant growth for Abbott/Eisai’s Humira in ulcerative colitis once indication is approved
29 November 2011
Eisai in deal with Novartis to co-promote COPD drugs in Japan
21 November 2011
UK’s NICE rejects Eisai’s Halaven for advanced breast cancer
17 November 2011
Mixed half-year results from Astellas, Eisai and Santen
2 November 2011
Helsinn moving forward with supportive cancer care products anamorelin and netupitant + palonosetron
26 September 2011
Regulatory briefs: Allergic reactions warning on Merck & Co’s Saphris; Eisai drops Pariet ER development
2 September 2011
Abbott and Eisai launch of PDER drug Lipacreon in Japan
31 August 2011
Arena and Eisai release data on obesity drug candidate lorcaserin to be used in CRL response
3 August 2011
Eisai epilepsy drug delayed by US FDA, but Zonegran use extension filing accepted in EU
1 August 2011
More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira
4 July 2011
Teva and Pfizer settle over Neurontin; France drops Champix; Actavis’ Aricept generic cleared
1 June 2011
Public Citizen says US FDA should immediately pull Eisai and Pfizer’s high-dose Aricept from market
19 May 2011
Eisai gets Swiss approval for Halaven
19 May 2011
Eisai debuts breast cancer drug Halaven in UK
20 April 2011
Brazil: PharmaPraxis in deal with Health Ministry to make MAbs; Eisai sets up subsidiary
8 April 2011
Eisai licenses bexarotene to Minophagen forJapan; Roche opts for Invida for Korean marketing
4 April 2011
New therapies for metastatic disease addressed in updated NCCN Guidelines for breast cancer
15 March 2011
Eisai realigns US operations, with 20% job cuts
9 March 2011
Eisai Ph III study for eritoran fails to meet primary endpoint, but perampanel filing due this quarter
26 January 2011
EMA advisory committee backs Gilenya, Halaven, Jevtana, Pravafenix and Trobalt, but negatives for Fampyra and Multaq
24 January 2011
Final appraisal from UK’s NICE backs improved treatment access for early Alzheimer’s disease; SMC negative for Nexavar
18 January 2011
Elan pays $206 million to settle with US DoJ over past Zonegran sales and marketing activities
17 December 2010
Abbott Labs files suit against Impax over Simcor patent challenge; Ranbaxy debuts generic Aricept in USA
29 November 2010
US unit of Eisai in research pact with Japanese university for amatuximab for pancreatic cancer
19 November 2010
Eisai and FORMA Therapeutics in broad drug discovery collaboration worth up to $20 million
18 November 2010
US FDA approves Eisai’s Halaven for metastatic breast cancer and expanded use for Shire’s Vyvanse
16 November 2010
Arena and Eisai say new lorcaserin Ph III data show statistically significant weight loss
11 November 2010
Abbott/Eisai's Humira emerges as market leader in psoriatic arthritis, garnering sales of over $500 million in 2009
5 November 2010
In another disappointment for obesity drug candidates, US FDA declines to approve Arena/Eisai’s lorcaserin
25 October 2010
Strong cancer drug results presented by Roche, Sanofi-Aventis, Merck KGaA, Amgen and Eisai at ESMO Congress
12 October 2010
UK’s NICE does about turn on Alzheimer’s drugs but unable to recommend Merck & Co/J&J’s psoriatic arthritis drug Simponi
7 October 2010
- Elan makes "transformational" acquisitions and a divestment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- New study shows UCB's Neupro reduces NSBP in RLS patient
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
